News | Robotic Systems | September 24, 2018

Corindus Announces First Live Transmission of Remote Robotic Demonstration at TCT 2018

Live telerobotic procedure broadcast from Mayo Clinic to TCT Main Arena

Corindus Announces First Live Transmission of Remote Robotic Demonstration at TCT 2018

September 24, 2018 — Corindus Vascular Robotics Inc. announced the first live transmission of a remote interventional procedure using the company’s CorPath platform was performed at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego on Sept. 22, 2018. The remote interventional procedure was broadcast live from Mayo Clinic to the TCT Main Arena. Utilizing CorPath GRX with developmental remote technology, combined with a telecommunications system to enable communication with the bedside staff, the operator at Mayo Clinic had the ability to remotely manipulate interventional devices within a porcine model's arteries while located in a different building.

The global shortage of skilled specialists who can treat emergent conditions, such as a heart attack or acute ischemic stroke, is significant and continues to be a growing problem. Remote treatment has the potential to enable physicians to conduct procedures from virtually any location, opening opportunities for more patients globally to receive the benefits of lifesaving procedures where minimizing time to treatment is critical.

Earlier this year, Mayo Clinic received a $3.3 million grant from The Leona M. and Harry B. Helmsley Charitable Trust to support a multi-phase, multi-year development program for remote robotic technology. Mayo Clinic is working with Corindus to explore telerobotics as a new treatment paradigm that gives rural and underserved populations across the globe access to time-critical vascular therapies.

"We believe it fitting that the first-ever live transmission of a remote interventional procedure took place at the 30th anniversary of the TCT meeting. Interventional cardiovascular medicine has made great strides in the last 30 years, and this milestone case represents an important forward step as we advance the access and treatment of coronary artery and other vascular diseases," stated Martin Leon, M.D., founder of the Cardiovascular Research Foundation.

For more information: www.corindus.com

Related Content

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Overlay Init